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a b s t r a c t
BACKGROUND: Metachronous penile metastasis of bladder cancer occurs very rarely. The clinical man-
agement of the disease involves complex problems, and the disease is associated with a poor prognosis.
The common mode of spread to the penis is by the retrograde venous route.
PATIENTS AND METHODS: A 68-year-old patient who was diagnosed with invasive bladder cancer under-
went 18F-ﬂuorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) for
staging purposes. An 18mm intracavernosal metastatic lesion was detected in the penis with a SUVmax
of 12.9.
RESULTS: After the administration of gemcitabine + cisplatin-based chemotherapy, remission was
observed in the metastatic penile lesion according to EORTC criteria (12mm, SUVmax: 9), and second
line chemotherapy program was planned.
CONCLUSION: Penile metastasis from bladder cancer is an indicator of poor prognosis. The patients with
penile metastasis poorly respond to therapy, despite the use of effective systemic chemotherapy. The
researchers of the current study achieved a partial response to chemotherapy in the current case of penile
metastasis. The disease-speciﬁc life expectancy is less than one year in these patients. Radical ablative
surgery does not contribute to survival; however, it offers an alternativemethod in symptomatic patients.
© 2015 The Author. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bladder cancer ranks ninth throughout the world with 380,000
new cases occurring every year [1]. 10–15% of the patients have
metastatic disease at the time of diagnosis. Despite the administra-
tion of radical therapies, 50% of the patientswithmuscular invasive
bladder cancer develop metastatic lesions within two years. The
patients died of these metastases [2]. Unusual metastatic sites for
urothelial carcinoma are documented. These sites include cardiac
tissues, small bowel, and salivary glands [3–5]. The ﬁrst penile
metastasis was reported by Eberth et al. in a patient with rectal
adenocarcinoma in 1870 [6]. The ﬁrst documented case of penile
metastasis fromprimary bladder cancerwas reported byNeumann
Abbreviations: FDG-PET/CT, 18F-ﬂuorodeoxyglucose-positron-emission tomog-
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radiotherapy; FNAC, ﬁne needle aspiration cytology; TCCa, transitional cell carci-
noma; MIP, maximum intensity projection.
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in 1882 [7]. The failure of conventionalmethods in the clinical stag-
ing of bladder cancer is the most important obstacle to predict
survival and planning of additional treatment protocols. Clinical
staging using bimanual palpation, CT, or MRI may often result in
over- and under-staging and have a staging accuracy of only 70%
[8,9]. This poses amore signiﬁcant problem in the presence of atyp-
ical metastases. In the present case, penile metastasis could not be
detected with CT scans. It is well-known that metastasis can occur
in normal-sized lymph nodes and tissue with normal appearance.
PET/CT scans that combine anatomic and functional images provide
more sensitive data in the detection of these lymph nodes and
metastatic foci. Furthermore, there is a great demand for a diagnos-
tic test offeringhighsensitivity andspeciﬁcity inpredicting residual
disease and monitoring response to treatment in these patients
after chemotherapy. 18FDG-PET/CT is the gold standard diagnostic
modality in the planning of second line chemotherapy programs
using RECIST, PERCIST, and EORTC. In this case, PET/CT was used
to evaluate the response of penile metastasis to chemotherapy.
The importance of PET/CT has been emphasized in the follow-up
of atypical metastases.
2. Case report
A 69-year-old male patient presented complaining of penile
pain due to muscle-invasive bladder carcinoma (TCCa, high grade).
http://dx.doi.org/10.1016/j.ijscr.2015.04.017
2210-2612/© 2015 The Author. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. PET/CT Imaging(pre-chemotherapy). (a) The coronal 18FDG-PET/CT scans show, (arrow: left lung metastasis), SUVmax: 10.9. (b) The coronal 18FDG-PET/CT scans
show, (arrow: pelvic lymph node metastasis), SUVmax: 9.9. (c) The coronal 18FDG-PET/CT scans show, (arrow: penile metastasis, 18mm), SUVmax: 12.6.
The bimanual physical examination revealed normal ﬁndings. The
penile examination revealed a 2 cm painful mass in the right cor-
pus cavernosum. Biochemical analyses were as follows: glucose,
151mg/dL; creatinine, 0.9mg/dL; urea, 45mg/dL; aspartate amino-
transferase, alanine aminotransferase, alkaline phosphatase, and
gamma glutamyl transferase levels were within normal ranges;
white blood cells, 7.42×103/L; hemoglobin, 12.9 g/dL; sodium,
137mmol/L; potassium, 4.3mmol/L; chloride, 102mEq/L; and cal-
cium, 8.9mg/dL. The patient’s medical history was remarkable
for diabetes mellitus and the patient was using oral anti-diabetic
agents. The patient was a nonsmoker. 18FDG-PET/CT was per-
formed for staging purposes and revealed metastasis in the right
supraclavicular lymph node, multiple lung metastases, external
iliac lymph node metastasis, and penile metastasis. Fine nee-
dle aspiration cytology (FNAC) of the penile swelling revealed
metastatic transitional cell carcinoma (Figs. 1 and 2).
After administration of gemcitabine + cisplatin-based
chemotherapy, the patient was re-evaluated with repeat 18FDG-
PET/CT scan. A partial response to therapy was obtained according
to the response criteria of European Organization for Research and
Treatment of Cancer (EORTC) (Fig. 3). The patient developed mul-
tiple liver metastases despite the administration of chemotherapy.
PET/CT ﬁndings of the patient are summarized in Table 1.
Table 1
PET/CT ﬁndings in this study (pre-chemotherapy and post-chemotherapy).
PET/CT ﬁndings Metastatic focus Size (mm) SUVmax
Pre-
CTx
Supraclavicular lymph node 10 2.7
Lung 20 and 26 10.9 and 10.6




Supraclavicular lymph node 0 0
Lung 23 and 34 15.2 and 8.9
Pelvic lymph node 24 and 61 14.8 and 19.7
Penile 12 9.0
3. Discussion
It is still unknown, why the penile metastasis is infrequent
despite the fact that penis has got rich vascularazition and intensive
venous communication with neighboring organs. There are around
500 case reports in the literature. The primary tumor foci were
pelvic cancers in 70% of these cases. Metastasis from the bladder
(28.6%), prostate (27.9%), and rectosigmoid (12.2%) tumors are the
most commonly encountered metastases [6]. In a review of 372
patients by Cherian et al., prostate, bladder, rectosigmoid and rec-
tum, and kidney were the most common sites for primary tumor
Fig. 2. (a) The axial CT scans show, (Undedectable Penile Metastasis). (b) The axial 18FDG-PET/CT scans show, (arrow: dedectable penile metastasis) SUVmax: 12.6.
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Fig. 3. PET/CT Imaging(post-chemotherapy). (a) The coronal 18FDG-PET/CT scans show, (arrow: penile metastasis, 12 mm), SUVmax: 9.0. (b) The axial 18FDG-PET/CT scans
show, (arrow: penile metastasis, 12 mm) SUVmax: 9.0. (c) Maximum intensity projection (MIP) images, (arrow: penile metastasis).
that exhibited penile metastasis (34%, 30%, 13%, and 8%, respec-
tively) [10]. Lymphomas, lung cancer, gastrointestinal tract tumors,
and bone and ureteral tumors rarely metastasize to the penis. The
metastasis most commonly occurs to corpus cavernosum. How-
ever, the tumors can also metastasize to the glans penis and corpus
spongiosum, urethra, and penis skin [11,12]. The mechanisms of
penile metastasis were described by Paquin and Roland in 1956
[13]. There are four possible ways of spread to the penis: (a) direct
inﬁltration; (b) during instrumental examination; (c) hematoge-
nous – either through arterioles, retrograde venous stream or as
a paradoxical embolism through an atrial septal defect; and (d)
through retrograde lymphatic permeation [13]. Mass, induration
and nodules are the initial presentation of penile metastasis in 51%,
priapism in 27%, urinary symptoms like hemorrage, hematuria,
incontinence, and irritative and obstructive symptoms in 27%, pain
in 17%, retention in 13% and skin lesions in 11% of the patients [14].
Cherian et al., reported that up to 40% patientswith penilemetasta-
sis may initially present with priapism, due to compromised penile
venous drainage. Pain, hematuria, and obstructive voiding symp-
tomsare rarer presentations [10]. Furthermore, the authors suggest
that metastasis must be considered if priapism has been detected
in urogenital cancers unless otherwise is proven. In most cases of
bladder carcinoma with penile metastases have also other organ
metastasis. So that at the time of diagnosis, these patients usu-
ally have disseminated disease and prognosis is dismal. Isolated
metastases of the penis are exceptionally rare event [15]. Approx-
imately 30% of all penile metastases are detected concomitantly
with the primary tumor, whereas remaining 70% present within a
mean interval of 18months after primary tumor detection [16]. The
diagnosis must be based on histopathological examination. This is
due to the fact that a pagetoid pattern of inﬁltration is seen, partic-
ularly with transitional cell carcinoma of the urinary tract and this
should be differentiated from primary Paget’s disease of the penis
[17]. The disease is differentiatedwith primary tumors of the penis.
The primary tumors of the penis mostly appear as superﬁcial skin
lesions, and secondary tumorsmostly occur in deeper locations [6].
Some premalignant and malignant primary diseases (Bowen’s dis-
ease, erythroplasia of queyrat, verrucos carcinoma, squamous cell
carcinoma, melanoma, sarcoma), some infectious diseases (tuber-
culosis, chancroid, syphiloma), and somecommonbenigndisorders
(Peyroni’s disease, nonmalignant priapism) should be taken into
consideration in the differential diagnosis of metastasis penile can-
cers [18]. US is often the ﬁrst diagnostic method employed and
MRI offers a valuable diagnostic tool in conﬁrming the diagnosis
and demonstrating the extent of the disease. However, although
conventional methods are valuable in the diagnostic workup, they
can sometimes fail to detect lesions, as was the case in the current
patient. Intracavernosal metastasis without causing any change in
penis anatomy in the current patient could not be detected on CT
scans; however, the lesion was visualized with FDG accumulation
on PET/CT detector. FDG-PET/CT is an important diagnostic tool in
the follow-up these foci and monitoring response to therapy after
chemotherapy. The treatment options vary depending on the per-
formance status of the patient, local stage of the primary tumor,
presence of other metastases, and prevailing symptoms. The treat-
ment options include local excision, partial or radical penectomy,
radiotherapy, and chemotherapy [19]. The optimal treatment of
penile metastasis requires a multidisciplinary approach that is cor-
related with the disease extent. The average survival in patients
with penile metastasis is 3.9 months from diagnosis and, with
extensive surgery and chemotherapy, a survival of 9.2 months has
been reported [20]. The surgical treatment of metastatic lesions
can be considered in small isolated lesions; however, surgery is
complicated in lesions located in proximal part of penis. Penec-
tomy is occasionally indicated after failure of other modalities
to palliate intractable pain. Radiotherapy can be given in these
cases.
In the study by Zhu et al., comprising eight patients, a painless
nodule was the most common symptom (80%), which is different
from the literature [21]. The mean time between the diagnosis of
primary tumor and the diagnosis of penile metastasis was 26.4
months (1–00). The mean time between the diagnosis of penile
metastasis and death was 11.4 months (4–23). This study also rec-
ommended radical ablative surgery only in symptomatic patients
[21]. The prognosis is poor due to presence of widespread metas-
tases inpatientswithpenilemetastasis, and6-monthmortality rate
is reported to be around 80%. The survival rate in penile metasta-
sis of bladder cancer is extremely low, with a mean of 47 weeks.
However, the studies have reported a survival up to nine years in
penile metastasis from prostate cancer. In other words, biological
behavior of the primary tumor is more important in terms of prog-
nosis [6,19]. Secondary penile tumors are usually associated with
disseminated disease and indicate a poor prognosis. Most of the
patients with penile metastasis have advanced disease and sur-
vival after the diagnosis is generally short, and 80% of the patients
die within six months [15].
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4. Conclusion
Penile metastasis from bladder cancer is an indicator of poor
prognosis and it is often a part of a systemic disorder. An isolated
penile metastasis from bladder cancer is an extremely rare condi-
tion. It is difﬁcult to detect atypical metastases of bladder cancer
such as penile metastasis using conventional techniques. 18FDG-
PET/CT is an important diagnostic tool used in staging of the disease
and evaluating response to therapy.
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